R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells.
Rafet Basar,May Daher,Nadima Uprety,Elif Gokdemir,Abdullah Alsuliman,Emily Ensley,Gonca Ozcan,Mayela Mendt,Mayra Hernandez Sanabria,Lucila Nassif Kerbauy,Ana Karen Nunez Cortes,Li Li,Pinaki P. Banerjee,Luis Muniz-Feliciano,Sunil Acharya,Natalie W. Fowlkes,Junjun Lu,Sufang Li,Stephan Mielke,Mecit Kaplan,Vandana Nandivada,Mustafa Bdaiwi,Alexander D. Kontoyiannis,Ye Li,Enli Liu,Sonny Ang,David Marin,Lorenzo Brunetti,Lorenzo Brunetti,Michael C. Gundry,Michael C. Gundry,Rolf Turk,Mollie S. Schubert,Garrett R. Rettig,Matthew S. McNeill,Gavin Kurgan,Mark A. Behlke,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +39 more
TL;DR: It is shown that deleting the nuclear receptor subfamily 3 group C member 1 (NR3C1) renders VSTs resistant to the lymphocytotoxic effect of glucocorticoids, and a protocol for the rapid generation of GMP-grade NR3C2-knockouts with high on-target activity and minimal off-target editing is developed.
Journal ArticleDOI
Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir
Cindy Ippoliti,A. Morgan,Dawn Warkentin,K. Van Besien,Rakesh Mehra,Issa F. Khouri,Sergio Giralt,James Gajewski,Richard E. Champlin,Borje S. Andersson,Donna Przepiorka +10 more
TL;DR: Foscarnet is a safe and effective agent for prevention of CMV disease in allogeneic transplant recipients unable to receive ganciclovir as a result of profound neutropenia and CMV-related mortality was 5%.
Journal ArticleDOI
Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy.
F. Montemurro,Gabriella Rondon,Naoto T. Ueno,Mark F. Munsell,James Gajewski,Richard E. Champlin +5 more
TL;DR: Analysis of the effect of maintenance endocrine therapy after high-dose chemotherapy with hematopoietic progenitor cell transplant on the progression-free survival of patients with hormone-dependent metastatic breast cancer showed that MET was significantly associated with improved median PFS.
Journal ArticleDOI
Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.
Aimaz Afrough,Rima M. Saliba,Amir Hamdi,Medhavi Honhar,Ankur Varma,A. Megan Cornelison,Gabriela Rondon,Simrit Parmar,Nina Shah,Qaiser Bashir,Chitra Hosing,Uday R. Popat,Donna M. Weber,Sheeba K. Thomas,Robert Z. Orlowski,Richard E. Champlin,Muzaffar H. Qazilbash +16 more
TL;DR: Achieving a hematologic complete response was associated with a significantly higher probability of achieving an organ response and a longer overall survival compared with patients who received no induction or CC before auto-HCT.
Journal ArticleDOI
A subset of virus-specific CD161 + T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.
Abdullah Alsuliman,Muharrem Muftuoglu,Ahmad Khoder,Yong Oon Ahn,Rafet Basar,Michael R. Verneris,Pawel Muranski,A. John Barrett,Enli Liu,Li Li,Kate Stringaris,Darius Armstrong-James,Hila Shaim,Kayo Kondo,Nobuhiko Imahashi,Borje S. Andersson,David Marin,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +19 more
TL;DR: It is suggested that CD4+CD161+ T cells with rapid efflux capacity contribute to the maintenance of viral-specific memory T cells in patients undergoing chemotherapy and have implications for the development of novel immunotherapeutic approaches.